- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00891995
Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The specific aim of this study is to determine if early restoration of metabolic control will improve C-peptide production compared to children receiving routine diabetes management and the secondary aim is to determine if allowing the islet cells to be less metabolically active will have an impact on the underlying autoimmune process.
Following completion of the baseline procedures (Mixed Meal Tolerance Test and blood sample collection), participants are randomized to either the Standard Treatment Group or the Intensive Treatment Group which includes 4-6 days of inpatient closed loop therapy followed by outpatient use of an insulin pump and continuous glucose monitor for diabetes management.
All subjects will be seen 7 times in the first year and 4 times in the second year for follow-up testing. Subjects who are still producing insulin after 2 years may be asked to return every 6 months for an additional 2 years.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
- Phase 3
Kontakte und Standorte
Studienorte
-
-
California
-
Stanford, California, Vereinigte Staaten, 94305
- Stanford University
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80010
- Barbara Davis Center for Childhood Diabetes
-
-
Connecticut
-
New Haven, Connecticut, Vereinigte Staaten, 06519
- Yale University
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Indiana University
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Vanderbilt University
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age 6.0 to <46.0 years
- Diagnosis of type 1 diabetes with initiation of insulin therapy within past 7 days (day 1 being the first day of insulin therapy)
- If participant is female with reproductive potential, willing to avoid pregnancy and pregnancy test negative.
- Willing to accept randomization to either the intensive diabetes management group or the standard care group.
- Willing to complete the planned 2 years of follow-up.
- Able to electronically transmit data monthly.
- Investigator believes that the participant (and parent/guardian for children) understands and agrees to comply with the study protocol and is capable of undertaking all necessary testing.
Exclusion Criteria:
- Currently pregnant or lactating, or anticipate getting pregnant in the next one year.
- Currently anemic (hematocrit level will be obtained at the screening visit).
- Chronic use of systemic steroids or other noninsulin pharmaceuticals that might affect glycemic control or the presence of a disease that is likely to be treated with such medications during the first two years of the study.
- Complicating medical issues that might interfere with study conduct.
- Inpatient psychiatric treatment in the past 6 months (if the participant is a minor, for either the participant or the participant's primary care giver).
- Currently participating in another type 1 diabetes treatment study, including an intervention trial for treatment of diabetic ketoacidosis.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Intensive Treatment
closed loop therapy (4-6 days), insulin pump (2 years), continuous glucose monitoring (2 years), home glucose monitoring (2 years)
|
Closed loop therapy for up to 4 to 6 days
Standard diabetes management using a home glucose meter.
Insulin pump use for 2 years
Continuous glucose monitor use for 2 years
|
Aktiver Komparator: Standard Treatment
home glucose monitoring (2 years)
|
Standard diabetes management using a home glucose meter.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
C-peptide Average Area Under the Curve (AUC) in Response to a Mixed Meal at 1 Year Following Enrollment.
Zeitfenster: At baseline, MMTT data were collected at 0 and 90 min; at 12 months, MMTT data were collected at 0 to 240 min post meal
|
In the primary analysis of the 12-month Mixed-Meal Tolerance Test (MMTT) results, the geometric mean (95% C.I.) of C-peptide average AUC (=AUC/time) was 0.43 (0.34, 0.52) pmol/ml in the intensive treatment group and 0.52 (0.32, 0.75) pmol/ml in the usual care group (P=0.49).
|
At baseline, MMTT data were collected at 0 and 90 min; at 12 months, MMTT data were collected at 0 to 240 min post meal
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
HbA1c
Zeitfenster: 1 Jahr
|
1 Jahr
|
|
Peak C-peptide in Response to a Mixed Meal at 1 Year Following Enrollment
Zeitfenster: 0 to 240 min post meal at 1 year MMTT
|
0 to 240 min post meal at 1 year MMTT
|
|
Incidence of the Loss of the 2 Hour Peak C-peptide < 0.2 Pmol/ml on a Semi-annual MMTT
Zeitfenster: 0 to 240 min post meal at 1 year MMTT
|
Outcome measure in the table is the incidence of 2 hour peak C-peptide>=0.2
pmol/ml.
Since the formal clinical trial stopped at 12 months due to lack of efficiency (later follow-up were used to collect data for secondary analyses by pooling the two groups), only the outcome at 12 months are reported.
|
0 to 240 min post meal at 1 year MMTT
|
Adverse Events (Severe Hypoglycemia)
Zeitfenster: 1 year
|
1 year
|
|
CGM Mean Glucose
Zeitfenster: 1 year
|
1 year
|
|
CGM Measured Glucose Outcomes
Zeitfenster: 1 year
|
Include a series of glucose indices created from CGM measured glucose data, such as % time with glucose values <=70 mg/dl, % time with glucose values within target range of 71-180 mg/dl, % time with glucose values >180 mg/dl, and glucose variability as measured by coefficient of variation.
These indices were calculated by giving equal weight to each of the 24 h of the day.
At least 24 h of CGM data were required for calculating these indices.
|
1 year
|
Daily Insulin Dose
Zeitfenster: 1 year
|
1 year
|
|
BMI Percentile
Zeitfenster: 1 year
|
1 year
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Jay S. Skyler, M.D., M.A.C.P., University of Miami
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Buckingham B, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA, Bremer AA, Slover R, Tamborlane WV; Diabetes Research in Children Network (DirecNet) Study Group; Type 1 Diabetes TrialNet Study Group. Effectiveness of early intensive therapy on beta-cell preservation in type 1 diabetes. Diabetes Care. 2013 Dec;36(12):4030-5. doi: 10.2337/dc13-1074. Epub 2013 Oct 15.
- Diabetes Research in Children Network (DirecNet) Study Group; Type 1 Diabetes TrialNet Study Group; Buckingham BA, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA, Bremer AA, Slover R, Cantwell M. The effects of inpatient hybrid closed-loop therapy initiated within 1 week of type 1 diabetes diagnosis. Diabetes Technol Ther. 2013 May;15(5):401-8. doi: 10.1089/dia.2013.0002. Epub 2013 Apr 9.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- DirecNet 012
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Diabetes Typ 1
-
Eledon PharmaceuticalsZurückgezogenSpröder Diabetes mellitus Typ 1Vereinigte Staaten
-
Shanghai Jiao Tong University School of MedicineRekrutierung
-
Hadassah Medical OrganizationUnbekanntUnkontrollierte Typ-1-Diabetiker
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)AbgeschlossenDiabetes mellitus Typ 1 | T1DM | T1D | Neu aufgetretener Diabetes mellitus Typ 1Vereinigte Staaten, Australien
-
Shanghai Changzheng HospitalRekrutierungSpröder Diabetes mellitus Typ 1China
-
Capillary Biomedical, Inc.AbgeschlossenDiabetes mellitus, Typ 1 | Diabetes Typ 1 | Diabetes mellitus Typ 1 | Diabetes mellitus, insulinabhängig, 1Australien
-
Spiden AGDCB Research AGRekrutierungDiabetes mellitus Typ 1 | Diabetes mellitus Typ 1 mit Hypoglykämie | Diabetes mellitus Typ 1 mit HyperglykämieSchweiz
-
Capillary Biomedical, Inc.BeendetDiabetes Typ 1 | Diabetes mellitus Typ 1 | Diabetes mellitus, Typ I | Diabetes mellitus, insulinabhängig, 1 | IDDMÖsterreich
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...UnbekanntDiabetes mellitus Typ 1 mit Hyperglykämie | Diabetes mellitus Typ 1 mit HypoglykämiePolen
-
Poznan University of Medical SciencesUnbekanntDiabetes mellitus Typ 1 | Remission von Typ-1-Diabetes | Chronische Komplikationen von DiabetesPolen
Klinische Studien zur Closed loop
-
Azienda Ospedaliera Cardinale G. PanicoAbgeschlossenSynkope, vasovagal, neural vermitteltItalien
-
University of PennsylvaniaRekrutierung
-
Christoph NissenAbgeschlossenSchlaflosigkeit | SchlafenSchweiz
-
Prasad Shirvalkar, MD, PhDNational Institute of Neurological Disorders and Stroke (NINDS); United States...Aktiv, nicht rekrutierendChronischer Schmerz | Verletzungen des Rückenmarks | Phantomschmerzen der Gliedmaßen | Schmerzen nach SchlaganfallVereinigte Staaten
-
Duke UniversityBeendetNeuropathischer SchmerzVereinigte Staaten
-
Stanford UniversityRekrutierung
-
University of CambridgeCambridge University Hospitals NHS Foundation TrustAbgeschlossenStörungen des Glukosestoffwechsels | Autoimmunerkrankungen | Diabetes Mellitus | Erkrankungen des endokrinen Systems | Diabetes mellitus, Typ 1Vereinigtes Königreich
-
MedtronicNeuroAbgeschlossenChronischer SchmerzVereinigte Staaten
-
Massachusetts General HospitalNoch keine RekrutierungSchizophrenieVereinigte Staaten
-
CES UniversityAbgeschlossen